Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 515-520

  Liu, Hongbiao ^a   Zhan, Hongwei ^a   Sun, Da ^a   Xu, Wei ^a   Ye, Xiaojuan ^a   Zhang, Hong ^a   Zhao, Chunlei ^a   Bao, Chengkan ^a   He, Gangqiang ^a   Yin, Feng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

153Sm EDTMP therapy; Factor analysis; Hematologic toxicity

Indexed keywords

LEXIDRONAM SAMARIUM SM 153;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CORRELATION ANALYSIS; FACTORIAL ANALYSIS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; BONE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 34548603589     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.350     Document Type: Article

References (15)

1. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000;88:2934.
2. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26:2.
3. 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med 2000;41:2043.
4. Chinese Medical Association. Section of Nuclear Medicine of Procedure Guideline of Clinical Technology 1st ed. [in Chinese] Beijing: Chinese People Army Medicine Publisher, 2004:185.
5. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207.
6. 131I-labeled- anticarcinoembryonic antigen antibodies. Cancer 1997;80:2749.
7. Pan H. Prevention and treatment of myelosuppression caused by chemotherapy [review; in Chinese]. J Pract Oncol 2002,17:76.
8. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362.
9. 153Sm-EDTMP for treatment of osseous metastases. [in Chinese] Chin J Nucl Med 1995;15:23.
10. Zhang H, Tian M, Li S, et al. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 2003;18:719.
11. 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun 1999;20:609.
12. Lattimer JC, Corwin LA, Jr, Stapleton J, et al. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med 1990;31:586.
13. Lattimer JC, Corwin LA, Jr, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med 1990;31:1316.
14. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments, and peptides in preclinical and clinical settings. Cancer Biother Radiopharm 2002;17:445.
15. Graham MC, Scher HI, Liu GB, et al. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999;5:1307.